Cory Hogaboam
Chief Scientific Officer Rein Therapeutics
Dr. Cory Hogaboam is the Scientific Founder of ReInTx and a leading investigator at Cedars-Sinai, where he focuses on the immunopathogenesis of pulmonary fibrosis and lung inflammation. With deep expertise in translational lung research, Dr. Hogaboam’s work explores the roles of immune cell networks, epithelial plasticity, and neuro-immune interactions in chronic lung diseases. His research has contributed significantly to understanding fibrosis progression and identifying novel therapeutic targets to improve patient outcomes.
Seminars
Understanding the complex interplay between immune responses, epithelial dysfunction, and regeneration failures is crucial for advancing early intervention strategies in IPF. This workshop will explore the molecular underpinnings of immune cell activity, inflammation, and epithelial repair in disease progression. Through expert insights, we will dissect how disrupted biological processes drive fibrosis and discuss emerging therapeutic approaches targeting immune and epithelial pathways.
Get ready to explore:
Epithelial Dysfunction & Regeneration Failure in IPF
- The molecular biology of epithelial injury and its role in disease progression
- Why failed regeneration is central to fibrosis development
- Emerging biomarkers linking epithelial signatures to disease severity
The Enigmatic Role of Inflammation in IPF
- Understanding the paradox: why anti-inflammatory therapies worsen outcomes
- The potential of immune-targeting therapies and companies exploring this space
Bridging Immunology & Fibrosis in IPF Treatment
- Key immune players: which inflammatory cells are present, and what role do they play?
- How immune modulation could be leveraged for therapeutic intervention
- The next steps in developing immune-based therapies for IPF
